InduPro Therapeutics announces strategic collaboration with Eli Lilly

InduPro announced a global strategic collaboration and licensing agreement, and equity investment, with Eli Lilly (LLY) to discover novel oncology treatments using InduPro’s proximity-guided platform. Under the terms of the agreement, the two companies will collaborate on up to three targets, for a total deal value of up to approximately $950M. Lilly will also make an equity investment in InduPro. Through the agreement, Lilly will gain access to InduPro’s proprietary AI/ML-enabled membrane interactomics platform. InduPro will lead early discovery efforts, applying its proximity-guided platform to identify co-target pairs and advance bispecific and multispecific antibody programs emerging from the collaboration. “Our partnership with Lilly underscores a shared commitment to advancing a new generation of tumor-selective medicines guided by the spatial biology of cancer,” said Prakash Raman, PhD, CEO of InduPro. “TAPAs represent a fundamentally new way to think about tumor antigens, and we’re thrilled that Lilly shares our vision of leveraging proximity-based biology to enable precision multi-specific therapeutics. We believe this partnership reflects growing confidence in our differentiated, proximity-guided approach to tumor targeting and its promise to improve the design and performance of ADCs and TCEs.”